Investor Relations

Company Overview

Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML).

Latest Financial Results

Q3 2017

Quarter Ended Sep 30, 2017

Latest 10-K

For Fiscal Year 2016

Download 10-K

Stock Information

Symbol

OTCQB: HGEN

Price

Change

Volume

52 week Low/High

Day Low/High

Contact Information

Investor Relations

MZ Group
Mike Cole
T: 949-259-4988
mike.cole@mzgroup.us

Transfer Agent

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
T: 800-662-7232
www.computershare.com